Compare Novo Nordisk A/S (NVO) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Repligen Corporation Common Stock — how do they compare? Novo Nordisk A/S trades at $38.68 (market cap $169.24B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Novo Nordisk A/S is far larger — about 15× Repligen Corporation Common Stock's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Repligen Corporation Common Stock for 0 Days on average.
| NVO | RGEN | |
|---|---|---|
Market Cap | $169.24B | $11.31B |
Volume | 9,314,273 | 1,216,919 |
Sector | Health | Health |
52-Week High | $63.98 | $194.57 |
52-Week Low | $35.29 | $102.87 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $187.94B | $11.20B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.06, down 1.35% on the day, with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and 59.82% ROE, while recent quarterly earnings consistently beat expectations. Technical indicators show oversold conditions with RSI at 85.35, though the stock faces resistance at $39 levels. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews of hemophilia treatments.
NVO presents a compelling value opportunity with a 9.67 P/E ratio below industry averages and 58.98% analyst buy ratings targeting $42.33. Strong cash flow generation ($119.1B operating cash flow) supports dividend payments and strategic acquisitions. Key risks include competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays, but the company's dominant GLP-1 market position and expanding oral formulations provide growth catalysts.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
